Resumen
BMS 181184 (BMS), an analogue of pradimicin, was administered intravenously to neutropenic mice infected with either a fluconazole- susceptible or a fluconazole-resistant clinical isolate of Candida tropicalis. BMS prolonged survival at doses >3 mg kg-1 day-1, and at higher doses reduced tissue counts in mice. BMS was less potent mg for mg than amphotericin B. Combined BMS and amphotericin B were no more effective than either of the individual drugs.
Idioma original | English (US) |
---|---|
Páginas (desde-hasta) | 181-184 |
Número de páginas | 4 |
Publicación | Medical mycology |
Volumen | 36 |
N.º | 3 |
DOI | |
Estado | Published - jun 1998 |
ASJC Scopus subject areas
- Infectious Diseases